CoChat
Sign Up
Cited by 210Pharmacology and Obesity TreatmentData-Driven Disease SurveillanceSocial Media in Health Education

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis.

Open access
Han, Sabrina H, Safeek, Rachel, Ockerman, Kyle, Trieu, Nhan, Mars, Patricia, Klenke, Audrey, Furnas, Heather, Sorice-Virk, Sarah·2023·Aesthetic Surgery Journal
DOI 10.1093/asj/sjad211
Open this paper in CoChat — free accountOpen PDF

Abstract

Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity. The off-label use of Ozempic (Novo Nordisk, Bagsværd, Denmark), the brand name of the GLP-1 agonist semaglutide, for cosmetic weight loss has been popularized by social media and celebrity influence. The aim of this study was to analyze with Google Trends (Alphabet Inc., Mountain View, CA) the recent search popularity of Ozempic and related GLP-1 agonists. The term “Ozempic” was analyzed with Google Trends. Search popularity was assessed in terms of relative search volume (RSV) over a 5-year period. Changes in RSV were further compared with other GLP-1 agonists, “Wegovy” (Novo NordisK) and “Mounjaro” (Eli Lilly and Company, Indianapolis, IN). Between March 2018 and February 2023, overall RSV in “Ozempic” grew exponentially in the United States. Simple linear regression analysis showed significantly increased RSV over time with an R2 of 0.915 and a regression coefficient of 0.957 (P < .001). When comparing “Ozempic,” “Wegovy,” and “Mounjaro” since June 2021 (FDA approval of Wegovy), Ozempic remained at the greatest RSV. One-way analysis of variance found statistically significant differences between the 3 search terms at all time points between December 2021 and February 2023 (P < .001). This study demonstrates a significant and growing public interest in Ozempic and related GLP-1 agonists. As the use of GLP-1 agonists for weight loss becomes more prevalent, plastic surgeons, particularly in the aesthetic setting, must be prepared for the downstream implications. Increased awareness, understanding, and further scientific studies led by plastic surgeons will help deliver the safest possible patient outcomes. Level of Evidence: 3:

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/asj/sjad211

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 2

  1. Synnott, Those weight loss drugs may do a number on your face
  2. Academy of Motion Picture Arts and Sciences, 2023, 95th Academy Awards

Cited by

Sorted by citations

Items 201–210 of 210

Related

See all

Metadata

Authors
Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S.
Affiliations
  • University of Florida Health (US)
  • University of Florida (US)
  • Stanford University (US)
Corresponding author
Sorice-Virk, Sarah
ORCID
Venue
Aesthetic Surgery Journal
Publisher
Oxford University Press (OUP)
Published
2023-07-04
Volume
44
Issue
1
Pages
60-67
ISSN
  • 1090-820X (ISSN-L)
  • 1527-330X
DOI
10.1093/asj/sjad211
OpenAlex
W4383186133
Cited by
210
References
26
Citations by year
2026: 70 · 2025: 85 · 2024: 44 · 2023: 11
FWCI
32.71
Type
journal article
Language
en
Open access
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • Aesthetic Surgery Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Epidemiology › Data-Driven Disease Surveillance
  • Social Sciences › Health › Social Media in Health Education
Keywords
semaglutide, GLP-1 receptor agonists, off-label drug use, public interest, search volume trends, Wegovy, Mounjaro, obesity treatment, social media influence, celebrity endorsement
MeSH terms
Semaglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, United States, Weight Loss, Glucagon-Like Peptide 1, Off-Label Use, Search Engine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review